Premium
First results from an intensified monitoring system to estimate drug related hospital admissions
Author(s) -
Schneeweiss Sebastian,
Göttler Martin,
Hasford Joerg,
Swoboda Walter,
Hippius Marion,
Hoffmann AnneKathrin,
Riethling AnnKatrin,
Krappweis Jutta
Publication year - 2001
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.0306-5251.2001.01425.x
Subject(s) - medicine , pharmacovigilance , pharmacy , emergency medicine , incidence (geometry) , population , confidence interval , medical emergency , drug , pediatrics , family medicine , environmental health , pharmacology , physics , optics
Aims An intensified monitoring system was set up to identify drug related hospital admissions and estimate population‐based incidences for commonly prescribed medications. Methods Pharmacovigilance‐centres systematically screened nonelective admissions to emergency rooms or departments of internal medicine for drug related hospitalizations (DRH). Clinical pharmacologists used standardized causality assessment. Service areas of each acute care hospital were defined by 5 digit postal codes that covered 60% of all admissions. Drug dispensing information was available through claims processed by regional pharmacy computing centres. Quarterly incidences were estimated by dividing the number of events by the number of treated patients. Results 435 DRHs were reported during five quarters. The incidence of ADRs leading to admissions varied for specific drug groups from 1.5/10 000 treated patients to 24/10 000. Quarterly variation of incidences was moderate except for insulin and calcium antagonists. 95% confidence intervals overlap for all quarters within each group. Incidences are sensitive to changes in the definition of the source population. Conclusions Our pharmacovigilance monitoring system allows comparisons of population‐based incidences of drug‐related hospitalizations among drugs and over time. It provides important information for risk management and monitoring outcomes of pharmaceutical quality management programmes.